摘要
目的探讨树突状细胞-细胞因子诱导杀伤细胞(DC-CIK)细胞过继免疫治疗联合奥沙利铂+卡培他滨(XELOX)方案化疗对进展期结直肠癌(CRC)患者的疗效。方法将104例进展期CRC患者按随机数字表法分为观察组和对照组各52例,观察组行DC-CIK联合化疗,对照组行化疗。检测患者治疗前后血清糖类抗原242(CA242)、糖类抗原19-9(CA19-9)、癌胚抗原(CEA)、T淋巴细胞亚群[自然杀伤性T(NKT)细胞、自然杀伤(NK)细胞、CD4^+、CD3^+、CD8^+]及白细胞介素-6(IL-6)、白细胞介素-2(IL-2)、干扰素-γ(IFN-γ)、肿瘤坏死因子-α(TNF-α)水平,评价患者近期疗效。结果观察组患者的缓解率(RR)为61.54%(32/52),疾病控制率(DCR)为75.00%(39/52),分别高于对照组的40.38%(21/52)和55.77%(29/52),差异均有统计学意义(P<0.05)。治疗后,两组患者血清CEA水平均低于治疗前,差异均有统计学意义(P<0.05);治疗后,观察组患者血清IL-2、IFN-γ、TNF-α、CD4^+、CD3^+、CD8^+及NKT细胞水平均高于对照组,差异均有统计学意义(P<0.05)。结论 CRC患者行DC-CIK细胞过继免疫治疗联合XELOX方案化疗可改善机体免疫功能,弥补单纯化疗所造成的免疫抑制,为安全有效的疗法。
Objective To analyze the efficacy of adoptive cellular immunotherapy of dendric cell and cytokine- induced killer cell (DC-CIK) combined with oxaliplatin + carboplatin (XELOX) chemotherapy in patients with advanced colorectal cancer (CRC). Method A total of 104 patients with CRC were randomized into observation group or control group by a random number table, with 52 cases in each, the observation group was treated with DC-CIK combined chemotherapy, while the control group was administered with simple chemotherapy. The level of serum carbohydrate antigen 242 (CA242), CA19-9 and carcinoembryonic antigen (CEA), as well as the T lymphocyte subsets [natural killer T (NKT) cells, natural killer (NK) cells, CD4+, CD3+, CD8+] and interleukin-6 (IL-6), IL-2, interferon-γ(IFN-γ), and tumor necrosis factor-α(TNF-α) were measured before and after treatment, and the efficacy was evaluated. Result The response rate (RR) in observation group was 61.54%(32/52), and disease control rate (DCR) was 75.00%(39/52), and both were higher than that in control group at 40.38%(12/52) and 55.77%(29/52), respectively, with statistically significant differences observed (P<0.05). After treatment, the serum level of CEA in both groups were decreased significantly (P<0.05);and the serum level of IL-2, IFN-γ, TNF-α, CD4+, CD3+, CD8+, and NKT cells in observation group were evidently higher than those in the control group, with statistically significant differences noted (P<0.05). Conclusion DC-CIK adoptive cellular immunotherapy combined with XELOX chemotherapy can significantly improve the immune function of CRC patients and compensate for the immunosuppression caused by chemotherapy alone, with acceptable safety and efficacy.
作者
王村
温珍平
梁俊青
WANG Cun;WEN Zhenping;LIANG Junqing(Department of Medical Oncology, The Inner Mongolia Autonomous Region Cancer Hospital, Hohhot 010000, Inner Mongolia, China)
出处
《癌症进展》
2019年第8期933-935,938,共4页
Oncology Progress
关键词
结直肠癌
免疫功能
细胞过继免疫治疗
树突状细胞
colorectal cancer
immune function
adoptive cellular immunotherapy
dendritic cell
作者简介
通信作者(corresponding author):温珍平,邮箱:songlly1980@163.com.
